Clinical Trials Browser

Phase 2 × INDUSTRY × etaracizumab × Clear all

NCT00066196 2008-01-15

Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00072930 2008-01-15

MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms